USPTO serial 85354510
EMS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BELENKER, ESTHER
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EMS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Sao Paulo, BR
Sao Paulo, BR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
LEWIS F. GOULD, J R.
LEWIS F. GOULD, J R. DUANE MORRIS LLP30 S 17TH ST FL 5PHILADELPHIA, PA 19103-4196UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Personal hygiene and cosmetic preparations, namely, shampoo; toilet soap; hair conditioner; deodorant; bath oil; skin cleansing lotion; moisturizing cream; sun care, sun block and sun tan lotion; body deodorant and perfumes; skin emollients; all excluding shaving products | ACTIVE | — |
| 005 | Medical, pharmaceutical, and therapeutic preparations for use with humans, namely, Statins (HMG-COA reductase Inhibitors), Oral broad spectrum penicillins, Acid pump inhibitors, Non-narcotic analgesics, anti-pyretics, multivitamins with minerals, medications for erectile dysfunction, plain Angiotensin-II antagonist, plain ACE inhibitors, non-steroidal plain Anti-Rheumatics, Expectorants, Oral fluoroquinolones, Systemic antihistamines, SSRI Antidepressants, Antiobesity preparations, Macrolides, Oral cephalosporins, Bisphosphonates for osteoporosis and related disorders, plain Beta-blocking agents, tranquilizers, plain Calcium antagonists, topical nasal preparations, Cyclo-Oxygenase inhibitor platelet aggregation inhibitors, Anti-epileptics, Antidiarrheal micro-organisms, Appetite stimulants, Agents for systemic fungal infections, ADP (Adenosine Diphosphate) receptor antagonist platelet inhibitors, Geriatric monophasic preparations with estrogen, Plain antiflatulents and carminatives, plain oral corticosteroids, iron supplements, Antispasmodic/analgesic combinations, plain Thiazides and analogues, Plain vitamin C and vitamin C salts, centrally acting Muscle relaxants, Simple biguanide, Plain vitamin B complex, Atypical antipsychotics, antihelmintics, antireumaticos and topical analgesics, Sulfonylurea antidiabetics, systematic hormonal contraceptives, H2 antagonists, Gynecological antifungals, Combinations with anti-hypertensives and/or diuretics, topical musculo-skeletal preparations, plain Potassium-sparing agents, Angiotensin-II antagonist combinations with antihypertensives (C2) and/or diuretics, plain BPH 5-alpha testosterone reductase inhibitors (5-ARI), Plain topical corticosteroids, Systemic corticosteroid combinations, Antidepressants, Throat preparations, Herpes antivirals, Systemic nasal preparations, wound healing agents with antibacterials and antifungals, dermatological preparations, Gastroprokinetics, Injectable cephalosporins, Fibrates, Topical dermatological antifungals, plain BPH alpha-adrenergic antagonists, plain Antihypertensives, urinary antiseptics, topical antibacterials, Iron combination supplements, corticosteroid combinations, Topical antivirals, Topical trichomonacides with antifungals, Vitamin C combinations, Plain antacids, laxatives, Intestinal anti-inflammatory agents, Cerebral and peripheral vasotherapeutics, Stomatologicals, Enemas, Oral anti-acne preparations, Androgens. Topical Scalp antifungals, ACE inhibitor combinations with antihypertensives (C2) and / or diuretics (C3), SNRI Antidepressants with antibacterials, Antimigraine triptans, Tetracyclines and combinations, plain Non-barbiturates, Alpha-glucosidase inhibitors, Mouth Antifungals, Calcium antagonists with cerebral activity, Potassium-sparing agents with thiazides and / or analogue combinations, Cold preparations without anti-infectives, Antiulcerants, Synthetic antifibrinolytics, Ocular decongestants, Sympathomimetics, Herbal hypnotics/sedatives, Nasal decongestants, systematic B2-stimulants, gynecological antibacterials, choleretics and cholekinetics, plain anticholinergics inhalants, Otic corticosteroid / anti-infective combinations, Vitamin D, Systemic trichomonacides, plain Injectable corticosteroids, Triphasic preparations, Antispasmodics, local topical Anesthetics, Gonadotrophins and ovulation stimulants, gynecological antiseptics, Ophthalmological corticosteroid and anti-infective combinations, Calcium supplements, anti-migraine preparations, Progestogens, amoebicides, Ophthalmological anti-infectives, anti-anemic preparations, folic and folic acids, Plain antispasmodics and anticholinergics, urinary antibacterials, Trimethoprim and similar formulations, simple glitazones, Antacids with antiflatulents or carminatives, systemic non-steroidal respiratory anti-inflammatories, topical anti-acne preparations, topical products used in viral infections, Glina simple, Gynecological antispasmodics, plain Vitamin E, Intestinal anti-infective antidiarrheal preparations, multivitamins without minerals; Anti-smoking products, namely, smoking cessation preparations; Immunosuppressants, Antiseptics and disinfectants for sanitary purposes; Bulk producers, namely, laxatives; Oral electrolyte replacers and tonics, Ophthalmic non-steroidal anti-inflammatories, Anti-pruritics and topical antihistamines, anesthetics, Anti-Alzheimer preparations, cholinesterase inhibitors, Vitamin B1combinations with vitamin B6 and/or vitamin B12, Urinary incontinence preparations, Plain antitussives, Nasal anti-allergic agents, Digestives for pharmaceutical purposes; enzymes for pharmaceutical purposes; Prenatal urological preparations, Conventional antipsychotics, Platelet CAMP enhancing platelet aggregation inhibitors, Serotonin antagonist antiemetics / antinauseants, Anti-parkinson drugs, estrogens, oral Progestogen-only preparations, Injectable broad spectrum penicillins, Neurotonics, Plain medium narrow penicillins, Intestinal adsorbent antidiarrheals, Cough / cold preparations with anti-infectives, Antitussives in combinations, Otic anti-infectives, estrogen with progestogen combinations. Ectoparasiticides and scabicides, plain loop diuretics, Cardiac dopaminergic agents, antiemetics and antinauseants, Magnesium supplements, vitamin B1 combinations, Plain cardiac glycosides, all of the aforementioned goods excluding dental pharmaceutical goods | ACTIVE | — |
| 035 | Commercialization services in the field of import and export of products, namely, assistance in business management and product commercialization, within the framework of a franchise contract with respect to pharmaceutical products, alopathic, homeopathic, veterinary, food, diet, hygiene, dressing, cosmetics, perfumes, sanitizing, phytosanitary, and domisanitary products, pharmaceutical inputs, drugs and related products, synthesis of antibiotic, fine chemistry and industrial chemistry, herbs for infusion, plant oils, powders for soft drinks; import and export agencies in the fields of pharmaceutical products, alopathic, homeopathic, veterinary, food, diet, hygiene, dressing, cosmetics, perfumes, sanitizing, phytosanitary, and domisanitary products, pharmaceutical inputs, drugs and related products, synthesis of antibiotic, fine chemistry and industrial chemistry, herbs for infusion, plant oils, powders for soft drinks | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 14, 2015 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 14, 2015 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 24, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 23, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 9, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 9, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 26, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 25, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 25, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 4, 2014 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 4, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 24, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 22, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 22, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 22, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 13, 2013 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 18, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 29, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 10, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 9, 2013 | ALIE | ASSIGNED TO LIE | — |
| May 1, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 30, 2013 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 30, 2013 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 30, 2013 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 30, 2013 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 20, 2012 | UNTD | REQUEST TO DIVIDE UNTIMELY, REFUSED, OR WITHDRAWN | — |
| Nov 20, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 16, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 16, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 16, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 16, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 14, 2012 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Nov 12, 2012 | EMRV | EMAIL RECEIVED | — |
| Nov 12, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 12, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 12, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 12, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 12, 2012 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 9, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 8, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 8, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 8, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 8, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 23, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 23, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 23, 2012 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Apr 23, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 5, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 5, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 5, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 30, 2011 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Jun 29, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 27, 2011 | NWAP | NEW APPLICATION ENTERED | — |